Learn More
From the Department of Gastroenterol­ ogy and Gastrointestinal Outcomes Unit, Rambam Health Care Campus and Rappa­ port Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel (I.M.G.); the Divisions of Gastroenterol­ ogy and Clinical Epidemiology, McGill Uni­ versity Health Centre, McGill University, Montreal (A.N.B.); and INSERM Centre(More)
BACKGROUND & AIMS Data indicate that cyclooxygenase-2-specific inhibitors cause less gastroduodenal mucosal damage than nonspecific NSAIDS, but their effects on the small bowel mucosa are less well recognized. In a multicenter, double-blind, placebo-controlled trial with video capsule endoscopy (VCE) we prospectively evaluated the incidence of small bowel(More)
GOALS To compare the impact of irritable bowel syndrome (IBS) on health related quality of life (HRQOI) for non-white and white IBS patients. BACKGROUND There are no reported data evaluating the HRQOL of non-white persons with IBS. STUDY SF-36 scores are compared between non-white IBS patients (n = 166), white IBS patients (n = 707), the general US(More)
BACKGROUND & AIMS Treatment of high-risk patients with nonbleeding adherent clots on ulcers is controversial. In a previous randomized trial, there was no benefit to endoscopic therapies compared with medical therapy for prevention of ulcer rebleeding. Our purpose was to test the hypothesis that patients treated with combination endoscopic therapy would(More)
OBJECTIVES Model for end-stage liver disease (MELD) score is now often used as an overall indicator of health status for patients with end-stage liver disease. However, there are no data evaluating the associations between MELD scores and patient reports of health-related quality of life (HRQOL). METHODS Two hundred-three patients with end-stage liver(More)
BACKGROUND Current guidelines recommend routine assessment of health-related quality of life (HRQOL) in patients with irritable bowel syndrome (IBS). However, physicians rarely have the time to measure HRQOL with the appropriate methodological rigor, and data suggest that HRQOL in patients with IBS is often estimated using inaccurate clinical gestalt. The(More)
BACKGROUND Treatment options for chronic hepatitis B virus (HBV) infection have disparate risks and benefits. Interferon has clinically significant side effects, and lamivudine is associated with viral resistance. In contrast, adefovir is safe and has lower viral resistance but is more expensive. The most cost-effective approach is uncertain. OBJECTIVE To(More)
BACKGROUND AND STUDY AIMS Population-based screening for colorectal cancer is widely recommended, with conventional colonoscopy considered to be the preferred diagnostic modality. However, compliance with screening colonoscopy is low and manpower capacity is limited. Capsule endoscopy might therefore represent a desirable alternative strategy. PATIENTS(More)
BACKGROUND Small bowel mucosal injury associated with non-selective non-steroidal anti-inflammatory drugs is being increasingly recognized. AIM To evaluate the incidence of small bowel injury in healthy subjects receiving celecoxib or ibuprofen plus omeprazole using video capsule endoscopy (VCE). METHODS Subjects with normal baseline VCE were randomly(More)
OBJECTIVES Assessment of health-related quality of life (HRQOL) outcomes in studies of liver disease and liver transplantation is necessary. Reliable and valid disease-targeted HRQOL measures are thus needed. The objective of this study was to develop a reliable and valid self-report HRQOL instrument for ambulatory adults with chronic liver disease. (More)